MAAT-YS Program for Young Adult Cancer Survivors
(MAAT-YACCS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a telehealth program called MAAT-YS, designed to assist young adults who survived childhood cancer and now face memory and attention issues due to their cancer or its treatment. Participants will engage in eight weekly 45-minute sessions, using a workbook and completing homework to enhance cognitive function and quality of life. The study seeks cancer survivors aged 18-39 who completed treatment at least a year ago, are cancer-free, and experience memory or other cognitive problems. As an unphased trial, this study provides a unique opportunity to contribute to research that could improve cognitive support for cancer survivors.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this telehealth-delivered MAAT-YS is safe for young adult cancer survivors?
Research shows that Memory and Attention Adaptation Training (MAAT) helps cancer survivors manage memory and attention problems. While specific safety data for the customized MAAT-YS for young adult cancer survivors is not available, similar therapies have been well-received.
In past studies, MAAT has helped survivors address memory and attention issues. These therapies usually avoid physical side effects because they rely on psychological techniques instead of medication. Participants often engage in activities like using workbooks and completing assignments, which are generally safe.
This trial is in the early testing phase, focusing on effectiveness and practicality rather than safety. Cognitive-behavioral therapies like MAAT typically lack serious side effects, making them a low-risk choice for participants.12345Why are researchers excited about this trial?
Researchers are excited about the MAAT-YS program because it offers a fresh approach to supporting young adult cancer survivors. Unlike traditional treatments that often focus on the physical aspects of recovery, MAAT-YS emphasizes cognitive-behavioral therapy to address emotional and psychological well-being. This program is tailored specifically to the unique challenges faced by young adults, aiming to improve their quality of life and mental resilience after cancer treatment. By targeting psychological health directly, MAAT-YS has the potential to complement existing care, leading to a more holistic recovery process.
What evidence suggests that MAAT-YS is effective for cancer-related cognitive impairment?
Studies have shown that cognitive behavioral therapy (CBT) can improve mental health and quality of life in cancer patients, particularly younger ones. Research indicates that CBT leads to moderate improvements, noticeably enhancing how patients feel and function. Early findings suggest that young adult cancer survivors often encounter cognitive and mental health challenges during and after treatment. In this trial, participants will receive MAAT-YS, a specialized CBT program designed to address these specific issues.13678
Who Is on the Research Team?
Robert J Ferguson, PhD
Principal Investigator
St. Jude Children's Research Hospital
Donna Posluszny, PhD
Principal Investigator
University of Pittsburgh
Are You a Good Fit for This Trial?
This trial is for young adult cancer survivors aged 18-39 who had non-CNS solid tumors or leukemia/lymphoma diagnosed before age 18, are at least a year post-treatment and cancer-free. They must have cognitive issues related to their cancer treatment, be fluent in English, able to use telehealth with internet access, and willing to consent.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive telehealth-delivered Memory and Attention Adaption Training (MAAT-YS) tailored for young adult childhood cancer survivors with cancer-related cognitive impairment.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including self-report measures of cognitive symptoms, quality of life, and treatment satisfaction.
What Are the Treatments Tested in This Trial?
Interventions
- MAAT-YS
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pittsburgh
Lead Sponsor
St. Jude Children's Research Hospital
Collaborator
Indiana University School of Medicine
Collaborator